Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow

Harbeck, Nadia; Sotlar, Karl; Wuerstlein, Rachel; Doisneau-Sixou, Sophie F.

doi:10.1016/j.ctrv.2013.09.014

Cited by 88 publications

(74 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The receptor status was ER positive in 22, ER negative in 15, PR positive in 14, PR negative in 23, HER2 positive in 12, and HER2 negative in 25 patients (Table 1) (Schinzinger, 1889;Beatson, 1896;Jensen and Jacobson, 1960;Horwitz and McGuire, 1975;Hudziak et al, 1987;Natali et al, 1990). Additional genetic and epigenetic biomarkers are needed because of cancer heterogeneity (Ellis and Perou, 2013;Harbeck et al, 2014;Li et al, 2014). In the present study we analyzed miRNAs that are examples of epigenetic factors.…”

Section: Resultsmentioning

confidence: 99%

“…Over time, understanding of the underlying disease mechanisms has evolved, beginning as a simple clinical description in Egyptian papyri in 1550 BC (Saber, 2010), through to pioneering research on estrogen dependency in the late 19th century (Schinzinger, 1889;Beatson, 1896), the discovery of estrogen receptors (ER) ( Jensen and Jacobsen, 1960), the introduction of progesterone receptors (PR) (Horwitz and McGuire, 1975), human epidermal growth factor 2 (HER2) (Hudziak et al, 1987;Natali et al, 1990), identification of BRCA1 (breast cancer type 1 susceptibility protein) in the early 1990s (Black and Solomon, 1993;Rowell et al, 1994), and in recent years (1999/2000), cDNA microarray-based intrinsic classifications of molecular subtypes-luminal, basal like, HER2 enriched, or normal like (Perou et al, 1999(Perou et al, , 2000, and the development of high-throughput gene expression platforms (Harbeck et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

“…The key to understanding the heterogeneity of breast cancer is to decipher the underlying complex molecular interactions (Perou et al, 1999;Kaufmann et al, 2013;Harbeck et al, 2014;Mayer et al, 2014). Breast cancerrelated genes have been extensively investigated (Ellis and Perou, 2013), but much less is known about epigenetic alterations such as microRNAs (miRNAs), DNA methylation, or histone modifications (Lehmann, 2014;Li et al, 2014;McDermott et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of microRNA-93, 190, 200b and Receptor Status in Core Biopsies from Stage III Breast Cancer Patients

Kołacińska

Morawiec

Pawłowska

et al. 2014

DNA and Cell Biology

View full text Add to dashboard Cite

Oncologists now favor more personalized treatment strategies in breast cancer patients. Gene expression analysis has been widely used, but less is known about epigenetic factors, for example, microRNAs (miRNAs). The aim of this study was to determine the relationship between selected miRNAs and receptor status in core biopsies sampled before preoperative chemotherapy in stage III locally advanced breast cancer (LABC) patients. In 37 LABC core biopsies, three miRNAs per sample were analyzed: hsa-miR-93-5p, hsa-miR-190a, and hsa-miR-200b-3p, and hsa-miR-103a-3p as an endogenous control (TaqMan Ò RT-PCR; Applied Biosystems). Receptor status was determined by a dedicated pathologist. The Mann-Whitney U, Shapiro-Wilk, and Levene's tests were used to compare related samples. Levels of miRNA-93 differed significantly in core biopsies of LABC patients with different expressions of ER (estrogen receptor) and PR (progesterone receptor). Higher levels of miRNA-93 were found in ER-negative ( p = 0.0027) and PR-negative patients ( p = 0.0185). Levels of miRNA-190 and 200b did not differ significantly in core biopsies of LABC patients who expressed ER and PR differently ( p = 0.7727, p = 0.9434, p = 0.6213, and p = 0.1717). Levels of 190, and 200b were not significantly different in core biopsies of LABC patients with different HER2 (human epidermal growth factor 2) expressions ( p = 0.8013, p = 0.2609, and p = 0.3222). The assessment of core biopsy miRNA profiles and receptor-based subtypes may identify new signaling pathways for improved breast cancer classification.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of microRNA-93, 190, 200b and Receptor Status in Core Biopsies from Stage III Breast Cancer Patients

Kołacińska

Morawiec

Pawłowska

et al. 2014

DNA and Cell Biology

View full text Add to dashboard Cite

show abstract

“…These factors aid in that sense but still the challenge is to identify those patients that would not benefit from adjuvant chemotherapy, resulting in an over-treatment. To solve this dilemma, there has been great interest in prognostic and predictive gene expression profiles development [36][37][38][39][40][41].…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer in Argentina: Feasibility for the Implementation of the New TNM Staging System 2018 in A Middle-Income Country

Kress¹

2018

J Can Epi Treat

View full text Add to dashboard Cite

Background: Breast Cancer (BC) is the most commonly diagnosed cancer amongst women worldwide and also in Argentine a "medium human development" and "middleincome" country with an estimated incidence rate of 71, 2 per 100,000 in 2012. The implementation of the new TNM system for the staging of BC proposed by the AJCC and published in the VIII edition (2017) implies a substantial change with respect to the number of parameters and the criteria used until the present.

show abstract

“…Oncotype Dx is one of the most validated multi-gene signatures and is commercially available [124]. It integrates expression of 21 genes into numerical index associated with time to relapse in adjuvant setting (RS, "Recurrence Score").…”

Section: Oncotype DXmentioning

confidence: 99%

Prediction of Response to Aromatase Inhibitors in Breast Cancer

Larionov

Miller

2015

Resistance to Targeted Anti-Cancer Therapeutics

View full text Add to dashboard Cite

Aromatase inhibitors (AIs) are major treatment options for the management of patients with breast cancer. The drugs are effective and response rates can be high. However, resistance, either primary or acquired during treatment, may occur. Optimal clinical management requires accurate predictors of response to identify those tumours, which are most likely to respond (so sparing patients with resistant tumours needless side-effects of ineffective therapy). Currently, oestrogen receptor (ER) status is the only factor used routinely to select for treatment with aromatase inhibitors, but a substantial proportion of ER-positive tumours fails treatment. There is, therefore, an urgent need to identify additional markers by which accurately to predict clinical response on an individual basis. Whilst other markers (such as progesterone receptors or HER2) have some predictive powers, individually they have limited utility for routine use. The hope is that discovery strategies based on genome-wide searches will identify novel markers that can be used as predictive indices. Molecular phenotyping of individual tumours could then be used to decide not only which patients should be treated with AIs but whether AIs should be used alone or in combination or in sequence with other targeted agents in order that clinical benefits are maximized. This chapter will focus on utility of routinely assessed biomarkers, multi-component indices and gene signatures and outline the future perspectives in studies aimed to AI response prediction.

show abstract

Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow

Cited by 88 publications

References 96 publications

Association of microRNA-93, 190, 200b and Receptor Status in Core Biopsies from Stage III Breast Cancer Patients

Association of microRNA-93, 190, 200b and Receptor Status in Core Biopsies from Stage III Breast Cancer Patients

Breast Cancer in Argentina: Feasibility for the Implementation of the New TNM Staging System 2018 in A Middle-Income Country

Prediction of Response to Aromatase Inhibitors in Breast Cancer

Contact Info

Product

Resources

About